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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• The safety profile of new drugs is not well
known at the time of market approval and
serious safety issues are regularly identified
for marketed drugs.
• Drugs intended to meet an unmet medical
need can be approved for the market with
less safety data than is usually required,
using the Exceptional Circumstances and
Conditional Approval applications in
European Central procedure.
• It is unknown whether for drugs approved
using Exceptional Circumstances and
Conditional Approval procedures have an
increased probability of serious safety issues
identified post approval than for drugs
approved through the standard procedures.
WHAT THIS STUDY ADDS
• Using the Exceptional Circumstances and
Conditional Approval procedures does not
lead to more post-marketing safety alerts or
safety-related withdrawals when used for
drugs with unmet medical needs.
AIMS
Regulatory requirements for new drugs have increased. Special
approval procedures with priority assessment are possible for drugs
with clear ‘unmet medical need’. We question whether these
Exceptional Circumstances (EC) or Conditional Approval (CA)
procedures have led to a higher probability of serious safety issues.
METHODS
A retrospective cohort study was performed of new drugs approved in
Europe between 1999 and 2009. The determinant was EC/CA vs.
standard procedure approval. Outcome variables were frequency and
timing of a first Direct Healthcare Professional Communication (DHPC).
An association between approval procedure and the time from market
approval to DHPC was assessed using Kaplan-Meyer survival analysis
and Cox-regression to correct for covariates.
RESULTS
In total 289 new drugs were approved. Forty-six (16.4%) were approved
under EC or CA, of which seven received a DHPC (15%). This was similar
to the standard approval drugs (243), of which 33 received one or more
DHPC (14%, P = 0.77). The probability of acquiring a DHPC for standard
approval drugs vs. EC/CA drugs during 11-year follow-up is 22% (95%
CI 14%, 29%) and 26% (95% CI 8%, 44%), respectively (log-rank P =
0.726). This difference remained not significant in the Cox-regression
model: hazard ratio 0.94 (95% CI 0.40, 2.20). Only drug type was
identified as a confounding covariate.
CONCLUSION
The EC/CA procedure is not associated with a higher probability of
DHPCs despite limited clinical development data. These data do not
support the view that early drug approval increases the risk of serious
safety issues emerging after market approval.
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Introduction
Increasingly, society has become aware that drugs not
only cure or prevent diseases but also can lead to consid-
erable patient harm. Adverse drug events, whether or not
due to (in)correct use of drugs, have been estimated to be
a leading cause of unplanned hospital admission [1, 2].
New drugs are allowed onto the market based on rela-
tively limited knowledge of their benefit–risk profile due
to inherent and well-known limitations in pre-approval
clinical trials [3]. Those trials are typically performed in
carefully selected patient populations not fully represent-
ing ‘real world’ patients, are of relatively short duration
and are primarily developed to determine efficacy [4].
They are not powered to detect rare adverse events,
adverse events with a high background incidence or
those related to the disease [5]. It is therefore not surpris-
ing that both in Europe and the USA for approximately
10% of all marketed drugs, serious adverse drug events
were identified post approval that had to be communi-
cated to healthcare professionals or patients [6, 7]. Con-
sistently, cardiovascular adverse events including QT
prolongation and hepatotoxicity were leading causes for
safety withdrawals of drugs [6, 7]. Acknowledging this
situation, regulatory authorities have increased their pre-
approval requirements over time. For example, thorough
QT studies have become part of many new drug applica-
tions since QT prolongation and associated life-
threatening arrhythmias have led to several drugs being
withdrawn from the market [8, 9]. More recently, the
debate on rosiglitazone has led the Food and Drug
Administration (FDA) to step up its pre-approval require-
ments for new drugs for diabetes, to demonstrate
absence of an excess risk of cardiovascular events [10].
The negative consequences are that drug development
times may increase, as do costs that are estimated
upward of $800m for the development of a new drug,
limiting development of all but the most lucrative drugs
[11].
This development may not be in the interests of
patients with a shortage of available treatment options
for their disease, such as HIV/AIDS, cancer and many
orphan diseases with unmet medical need. This is why
the FDA introduced the Accelerated Approval (AA) proce-
dure in the USA and the European Medicines Agency
(EMA) the Exceptional Circumstances (EC) or Conditional
Approval (CA) procedures in Europe to approve drugs
based on more limited clinical data sets. In Europe, the EC
and CA procedures do not shorten the approval proce-
dure itself, as is a common misconception. In the case of
AA and CA procedures, companies are required to
perform confirmatory studies post approval, whereas in
the case of EC approval this is sometimes considered not
realistic, e.g. due to the (extreme) rarity of the disease [12,
13]. However, an earlier effort by the FDA to streamline
the regulatory process, the Prescription Drug User Fee Act
(PDUFA) that restricted review times of new drugs, was
criticized as it may have led to unsafe drugs being
approved [14]. Since the EC procedure has been used
since 1995 and the CA procedure since 2007, it seems
opportune to evaluate whether these special approval
procedures have led to more safety issues identified after
the drugs were marketed.
Our study evaluates whether the early approval under
EC or CA has led to a higher probability of new serious
safety issues post approval than for drugs approved with
the standard procedure of the EMA.
Methods
Study design and study population
A retrospective cohort study was performed including all
new active substances approved under the European Cen-
tralized Procedure (CP) from 1 January 1999 to 31 Decem-
ber 2009, using a limited definition of new active
substances, by excluding biosimilars as defined by Eichler
et al. [15, 16]. The determinant was whether the drug
product was approved using EC/CA or the standard proce-
dure. Regulatory and scientific information on drugs was
obtained from the European Public Assessment Report
(EPAR), which is a summary report of the application. EPARs
are issued for drugs that have received a marketing autho-
rization under the European Centralized Procedure (CP).
EPARs are publicly available and can be retrieved from the
EMA website [17].
Outcome
The primary outcome was the identification of a first
serious safety issue post approval. A serious safety issue
was defined as an issue requiring regulatory risk commu-
nication in the form of a Direct Healthcare Professional
Communication (DHPC) or a safety-related withdrawal of
the marketing authorization.
A DHPC contains information aimed at ensuring safe
and effective use of medicinal products. It is delivered
directly to individual healthcare professionals by a Market-
ing Authorization Holder or by a Competent Authority.
DHPCs issued for drugs approved with the European CP
were retrieved from the Dutch Medicines Evaluation Board
website [18]. We included European DHPCs issued from 1
January 1999 to 31 December 2009 and excluded DHPCs,
where the safety issues were related to the administration
of the drug, the pharmaceutical quality of the product or to
malfunctioning in a device for the administration of the
drug.
Time to DHPC or safety-related market withdrawal,
defined as the time in months from the date of market
approval to the date of a first DHPC or withdrawal,
was assessed. Whether a withdrawal was safety-related
or not, was determined from the EMA press release
Additional safety risk to exceptionally approved drugs in Europe?
Br J Clin Pharmacol / 72:3 / 491
regarding each drug withdrawal, as retrieved from the
EMA website.
Covariates
Covariates were defined that could be considered as
potential confounders.These were related to the drug, pro-
cedural issues and the clinical development and were
obtained from the EPAR. The factors related to the drug
were drug class [on anatomical therapeutic and chemical
(ATC) code [19] ATC-2 level, where more than five drugs
were approved through the EC or CA procedure], whether
it was first in class (yes/no) and the type of drug (small
molecule or biological including vaccines) as these might
influence the likelihood of receiving EC or CA marketing
authorization as well as potentially increase the risk of
serious safety issues post approval. The procedural issue
was orphan drug status (yes/no), because orphan drugs
could be more prone to receiving EC or CA market
approval and might be less prone to issuance of DHPCs.
Another potentially important factor in the marketing
authorization application dossier related to the clinical
development process was the size of safety population
(less than 1500 subjects, yes/no). EC/CA drugs can more
often be approved with less than 1500 subjects exposed
and drugs with smaller exposure in patients/healthy vol-
unteers before approval may lead to more adverse drug
reactions only being identified after approval.This number
of 1500 has been specified by the E1 document published
by the Internal Conference on Harmonization (ICH), agree-
ment between USA, European and Japanese regulators, as
a minimum number of subjects/patients who are expected
to be exposed pre-approval to any new drug product [20].
Analysis
Differences between baseline characteristics were analysed
using chi-square and are presented in Table 1. The probabil-
ity for EC/CA and drugs approved with standard procedure
to receive a DHPC or to be withdrawn for safety reasons was
evaluated by Kaplan Meyer analysis correcting for follow-up
duration and by the log-rank test. A follow-up duration of 11
years was deemed appropriate, as 73% of DHPCs are issued
in the first 10 years after market approval [7].
Our study had 80% power at a 5% a-level to detect a
difference of 10% between EC/CA and drugs approved
with standard procedure of identifying safety-related
issues requiring a DHPC during the 11-year follow-up. This
is considering that 280 new drugs obtained marketing
authorization during the study period and had a 20% base-
line chance for acquiring a DHPC, which is approximately
in between the estimation for biologicals (29%) [21] and
for all drugs (10%) [6] during 10-year follow-up.
A multivariable Cox proportional hazard model (HR and
95% CI) was used to evaluate the association between
approval type and time to first DHPC, correcting for con-
founding covariates (P < 0.1 in the chi-squared analyses). A
sensitivity analysis was also performed including all cova-
riates in the Cox model.
As the research did not involve any patient data or
other confidential material, no ethics approval was neces-
sary for the performing of the study.
Table 1
Approval procedures and issuance of a DHPC for new active substances (NAS) approved between 1 January 1999 and 31 December 2009 and drug,
procedural issues and clinical development characteristics
All NAS Approval DHPC




P**n (%)* n (%)* n (%)* n (%)*
Total 289 (100) 46 (100) 243 (100) 40 (100) 249 (100) 0.94 (0.40, 2,20)
Drug
Drug classes (ATC-2 level§) <0.001† 0.014
Alimentary tract and
Metabolism – other (A16) 13 (5) 7 (15) 6 (3) 1 (3) 12 (5) 0.57 (0.07, 4.43)
Direct acting antivirals (J05) 19 (7) 8 (17) 11 (5) 7 (18) 12 (5) 3.07 (1.28, 7.37)
Antineoplastics (L01) 38 (13) 11 (24) 27 (11) 7 (18) 31 (12) 1.62 (0.69, 3.83)
Other drug classes ‡ 219 (76) 20 (44) 199 (82) 25 (63) 194 (78) reference
First in class (y) 37 (13) 5 (11) 32 (13) 0.669 6 (15) 31 (12) 0.654 –
Biologicals (y) 109 (38) 14 (30) 95 (39) 0.266 13 (33) 96 (39) 0.463 –
Procedural issues
Orphan drugs (y) 55 (19) 20 (44) 35 (14) <0.001 7 (18) 48 (19) 0.790 –
Clinical development
Safety population <1500 (y)¶ 157 (56) 38 (83) 119 (51) <0.001 23 (59) 134 (56) 0.694 –
*Percentages are expressed within NAS, approval type and DHPC (column). **P value of chi square, statistically significant values are presented in bold. ***Cox-proportional hazard
ratio corrected for covariates presented. †Drug classes are selected to over-represent EC/CA procedure (five drugs registered through EC/CAA procedure). ‡All drugs that are not
categorized on ATC-2 level as A16, J05 or L01. §Variable is categorical and ratio of values adds up to 100%, presented with numbers in italics. (y) Variable is dichotomous and value
represents the ‘yes’. ¶EPARs were not available for nine drugs, thus the size of the safety population could not be established for those nine drugs. The ratio presented is for the
280 NAS with EPARs available. CA, Conditional Approval; DHPC, Direct Healthcare Professional Communication (as proxy for safety issues) after excluding non-safety-related DHPCs;
EC, Exceptional Circumstances.
A. H. Arnardottir et al.
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Results
Of the 289 new drugs that obtained a marketing authori-
zation between 1 January 1999 and 31 December 2009, 46
(16%) were approved under EC/CA, of which 38 were with
EC approval and eight with CA. In the study period, two to
10 EC/CA drugs were approved annually, without any
obvious pattern (Figure 1). Sixteen drugs were withdrawn
from the market for commercial reasons, all approved with
standard procedure. The medium follow-up of those with-
drawn drugs was 45 months.
In total 74 DHPCs were issued for 49 of the 289 drugs
included, with 16 drugs receiving more than one DHPC.
Five drugs, all approved with standard procedure, were
withdrawn because of safety concerns: inhaled insulin,
efalizumab, rimonabant, valdecoxib and a combination
vaccine (Hexavac™). Eleven DHPCs for nine drugs were
excluded: for five drugs the safety issues were related to
the administration of the drug, for three drugs to the phar-
maceutical quality of the product and for one drug to a
malfunction in a device for the administration of the drug.
A list of all DHPCs is presented in Appendix 1. Of the 46
drugs with EC/CA approval, seven received a DHPC (15%)
in comparison with 33 of 243 standard approvals (14%,P =
0.77). DHPCs for three EC approved drugs (drotecogin alfa,
atazanavir and tenofovir) regarded lack of efficacy con-
cerns in certain subpopulations. All other DHPCs con-
cerned safety issues.
The mean follow-up duration, from the date of approval
to a first DHPC,withdrawal or end of study period,for EC/CA
and standard approved drugs, was 52 months (95% CI 42,
62) and 55 months (95% CI 50, 60), respectively.The Kaplan
Meyer derived probability for drugs receiving a DHPC was
similar for both types of approval processes (Figure 2; log-
rank P = 0.726). At 3-year follow-up, drugs under EC/CA
approval had a 7% (95% CI 0%, 15%) risk of receiving a
DHPC, while standard approvals had a 10% (95% CI 6%,
14%) risk of receiving a DHPC. At 11-year follow-up, this risk
was 26% (95% CI 8%, 44%) for EC/CA approved drugs and
22% (95% CI 14%, 29%) for standard approved drugs.
The unadjusted hazard ratio (HR) for EC/CA drugs to
receive a DHPC during the follow-up was 1.16 (95% CI 0.51,
2.62). When correcting for confounders, the EC/CA drugs
had a 0.94 (95% CI 0.40, 2.20) HR to receive a DHPC during
the follow-up in the Cox proportional hazards model. From
the confounders hypothesized to be present, the distribu-
tion of ‘drug classes’ (ATC-2 level) was significantly different
between drugs approved under EC/CA and standard con-
ditions (P < 0.001), as the drug classes were specifically
selected to have more than five drugs licensed under
EC/CA.As could be expected, EC/CA drugs were more likely
to be orphan drugs (44%) than the drugs approved with the
standard procedure (14%,P < 0.001) and more EC/CA drugs
(83%) had safety populations that did not meet the ICH
threshold of 1500 patients exposed to a new drug before





























Proportion of new active substances (NAS) that obtained a marketing authorization between 1999 and 2009 under exceptional circumstances/conditional
approval (EC/CA) or standard marketing authorizations with or without a Direct Healthcare Provider Communication (DHPC)
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(51%,P < 0.001). For nine drugs we were unable to retrieve
the variable ‘size of the safety population’ as scientific dis-
cussion of the EPARs was no longer available on the EMA
website. All these drugs have been withdrawn from the
market. However, only drug class was associated with the
issuance of a DHPC (P = 0.014) and was subsequently
included in the Cox model as a potential confounder
(Table 1). In the sensitivity analysis that incorporated all
covariates, the results were similar.The approval procedure
did,however,not affect the issuance of DHPCs.For example,
38% (three of eight) EC/CA and 36% (four of 11) HIV AIDS
drugs approved with standard procedure received a DHPC.
HIV/AIDS drugs had an increased risk of a DHPC, HR 3.07
(95% CI 1.28, 7.37) independent of the approval procedure.
Discussion
In the EU, drugs receiving approval through the EC or CA
procedure have a similar probability of a first serious safety
issue requiring a DHPC as drugs approved with standard
procedure in our 11-year follow-up study, 26% and 22%,
respectively. None of the EC/CA, but five of the drugs
approved with standard procedure were withdrawn from
the market because of safety concerns.
In this direct comparison of approval procedures, no
association could be found between approval procedure
and identification of serious safety issues post approval.
Recent examples have shown the need for continuous
monitoring of the benefit risk balance during the lifecycle
of a drug [7]. This has led to a more proactive approach of
pharmacovigilance through risk management plans. In the
risk management plan, based on the knowledge of the
drug’s characteristics at the time of the approval, gaps in
data are identified, companies are required to obtain addi-
tional data on benefits and risks of the drug in daily practice
or in post-marketing trial settings [22, 23]. Since the EC/CA
drugs have been approved on preliminary evidence, regu-
lators usually require even stricter risk management plans
[12, 13, 24]. This close follow-up is expected to be more
sensitive in picking up important safety issues than rou-
tinely collecting spontaneous adverse drug reactions,
which is the usual approach for drugs approved with the
standard procedure.Balancing this effect of close follow-up
is that EC/CA drugs are generally intended to treat
rare diseases and not all European countries reimburse
conditionally approved drugs. Therefore, the population
exposed to these drugs post approval may still not be suf-
ficiently large to detect less common adverse drug reac-
tions. Heemstra et al. consider this a likely explanation for
their observation of orphan drugs having fewer safety
issues post approval than biologicals or (all) new drugs in
cross-study comparisons [24].Support for their explanation
is that they observed an association of safety-related regu-
latory action for drug classes with the highest expected
use, those orphan drugs used within oncology and gastro-
enterology and metabolic indications (ATC classes L01/L02
and A, respectively). In our study these drug classes and
drugs to treat HIV/AIDS (ATC class J05) were also over-
represented in the EC/CA group. Moreover, drug classes
and specifically those involving the HIV/AIDS drugs were
shown to truly confound the results,for which we corrected
in the Cox-proportional hazard model, as they also more
frequently led to a DHPC. HIV/AIDS drugs are the most
commonly used EC/CA drugs, which may indeed explain


































































Proportion of new active substances authorized under exceptional circumstances/conditional approval (EC/CA) or standard conditions with a subsequent
Direct Healthcare Provider Communication (DHPC)
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early. Our data, however, also showed that for both HIV/
AIDS and anti-cancer (data not shown) drugs, the approval
procedure did not predict whether serious safety issues
were identified more readily post approval. Unfortunately,
data on drug usage could not be obtained. Many of the EC
and CA licensed drugs are used in a hospital setting and
hospital drug consumption data are not readily available in
the Netherlands or for the EU as a whole. Also, reimburse-
ment is different across EU countries and associated pre-
scription data difficult to obtain. This needs further study,
perhaps in a setting where comprehensive total drug
usage is available. Our results are in line with Richey et al.
[25], who concluded that anti-cancer drugs approved with
the accelerated approval were safe because none was with-
drawn. They also confirm the more limited analyses by
Boon et al. [26]. However, Boon et al. included in their
assessment all withdrawals, not discriminating between
withdrawals due to safety issues and withdrawals for com-
mercial reasons.
Our finding that EC/CA drugs that were approved with
more limited clinical data sets are as safe as drugs
approved with the standard procedure seems at odds with
the current societal demand for more pre-approval ascer-
tainment of harms and benefits of new drugs [10, 11, 27,
28]. This finding has important societal implications. The
request for large-scale outcome studies, for example, for
new drugs for diabetes may already be prohibitive even in
a field with a large target population. Therefore, it is reas-
suring to learn that EC/CA registration with limited clinical
data sets seems to have been safe in the past decade for
drugs with high unmet medical need.
Reassuringly, only three DHPCs were issued because of
efficacy concerns from confirmatory trials, indicating that
the objective to allow early access of potentially effective
drugs meets its expectations.
Although we showed in an earlier study that approxi-
mately 10% of all marketed drugs throughout their life-
cycle required safety-related regulatory action [7],we found
in this study that for more recently approved drugs within
11 years after that approval, the probability of requiring a
DHPC is 26%. This is higher than reported earlier by Lasser
et al. [6] but in line with Giezen et al., who reported similar
probabilities for biologicals [21]. Lasser et al. included all
drugs on the market in the USA from 1975 to 1999,while the
study done by Giezen et al. was more recent and included
only biological drugs approved in Europe and the USA
between 1995 and 2007. Our finding is consistent with the
increasing trend of regulatory risk communications
(DHPCs) per year that we observed in our earlier study [7].
The difference between our results and Giezen et al. ’s on
one hand, and those of Lasser et al. on the other, could be
due to increasing risk awareness, or to the implementation
of more sensitive pharmacovigilance tools.
With this apparent growing risk awareness, it was
remarkable that 51% of all drugs with regular authoriza-
tion did not meet the ICH guideline of at least 1500
subjects exposed to the drug in pre-approval trials (safety
population), in particular because this ratio is rather
constant throughout the study period (data not shown).
It would be a topic of future research to explore why
the safety population is so limited in the marketing autho-
rization procedure. However, one must keep in mind that
the safety requirements in the EU and ICH guidelines are
merely a guide. A complete cure for a rapidly fatal disease
would require relatively few patients, while, to establish
clinical benefit and an absence of harm, for a new surro-
gate endpoint may take many thousand patient years.
Limitations of the study
Direct Healthcare Professional Communications might not
be the most sensitive proxy for safety issues and could be
handled or perceived differently for EC/CA drugs address-
ing ‘unmet medical needs’. The acceptability of serious
safety issues in the overall benefit/risk balance may be
higher and could have a higher threshold for issuing a DHPC
resulting in less strong safety-related regulatory action,
such as a change in the Summary of Product Characteristics.
However, this does not become apparent when the
observed safety issues reported for EC/CA are considered
vs. those for regularly approved drugs (Appendix 1). Fur-
thermore, the DHPC is recommended as the risk communi-
cation tool to guarantee continued safe use of a drug [29].
Other studies have used the DHPC as the most important
proxy of serious safety issues [6,21,24].It is the best we have
as an overall measure that is going through a careful evalu-
ation procedure at the EU level.
We cannot be completely sure that drugs withdrawn
from the market for commercial reasons do not also have a
safety issue prompting the company’s decision to with-
draw the drug. However, in the reported cases the EMA
press releases explicitly mentioned either that safety con-
cerns were not the reason for withdrawal or that commer-
cial reasons prompted the withdrawal.
As mentioned, EC/CA drugs are used in relatively small
patient populations, which reduces the chance of finding
rare adverse events. Therefore, our conclusion for the
EC/CA procedure does not imply that this procedure
would be appropriate for all drugs.
In conclusion, our study showed that the risk of receiv-
ing a DHPC is similar for those drugs licensed using EC and
CA and the drugs that were licensed using the standard
procedure in the past 11 years in the EU.
The use of EC and CA should be continued, as it is
valuable in allowing earlier entry to the market for eligible
drugs that are mostly intended for rare diseases,without an
apparent increased risk of unexpected serious side effects.
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Appendix 1
Drugs with safety issues




Rimonabant* A08AX01 June 2006 Depression Psychiatric disorders 1.1
Depression Psychiatric disorders 2.1
Depression Psychiatric disorders 2.4
Insulin human
(inhalation)*





Rosiglitazone A10BG02 July 2000 Macular oedema Eye disorders 5.5
Fracture Musculoskeletal and connective
tissue disorders
6.6
Pioglitazone A10BG03 October 2000 Fracture Musculoskeletal and connective
tissue disorders
6.5
Eptifibatide B01AC16 July 1999 Drug therapy changed Surgical and medical procedures 7.7
Tipranavir J05AE09 October 2005 Haemorrhage intracranial Nervous system disorders 0.8
Abacavir J05AF06 July 1999 Drug hypersensitivity Immune system disorders 8.7
Myocardial infarction Cardiac disorders 8.8
Entecavir J05AF10 June 2006 Pathogen resistance Infections and infestations 0.7






J07CA October 2000 Drug ineffective General disorders and
administration site conditions
4.9
Trastuzumab L01XC03 August 2000 Cardiotoxicity Cardiac disorders 0.8
Cardiotoxicity Cardiac disorders 1.7
Bevacizumab L01XC07 January 2005 Tracheo-oesophageal fistula Congenital, familial and genetic
disorders
2.3
Eye disorder Eye disorders 4.1
Imatinib mesilate L01XE01 November 2001 Urinary bladder adenoma Renal and urinary disorders 3.4
Cardiac failure Cardiac disorders 5.1
Temsirolimus L01XE09 November 2007 Anaphylactic reaction Vascular disorders 1.2
Erlotinib L01XX34 September 2005 Gastrointestinal perforation Gastrointestinal disorders 3.7





Efalizumab* L04AA21 September 2004 Progressive multifocal
leukoencephalopathy
Nervous system disorders 4.4
Etanercept L04AB01 February 2000 Blood disorder Blood and lymphatic system
disorders
0.7
Infection Infections and infestations 3.0
A. H. Arnardottir et al.
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Appendix 1
Continued
Drug name ATC Approved Warning System organ class
Time to
DHPC (years)
Infliximab L04AC03 August 1999 Tuberculosis Infections and infestations 1.4
Cardiac failure Cardiac disorders 2.2
Infection Infections and infestations 2.5
Lymphoma Blood and lymphatic system
disorders
6.8
Leflunomide L04AA13 September 1999 Hepatitis Hepatobiliary disorders 1.5
Anakinra L04AC03 March 2002 Infection Infections and infestations 0.9
Efalizumab L04AA21 September 2004 Progressive multifocal
leukoencephalopathy
Infections and infestations 4.1
Natalizumab L04AA23 June 2006 Progressive multifocal
leukoencephalopathy
Infections and infestations 2.1
Adalimumab L04AB04 September 2003 Hepatosplenic T-cell lymphoma Blood and lymphatic system
disorders
4.9
Lenalidomide L04AX04 June 2007 Maternal drugs affecting foetus Injury, poisoning and procedural
complications
0.4
Teratogenicity Congenital, familial and genetic
disorders
1.2
Valdecoxib* M01AH03 March 2003 Cardiovascular disorder Cardiac disorders 1.7
Cardiovascular disorder Cardiac disorders 1.8
Cardiovascular disorder Cardiac disorders 1.9
Cardiovascular disorder Cardiac disorders 2.1
Parecoxib M01AH04 March 2002 Hypersensitivity Immune system disorders 0.6
Cardiovascular disorder Cardiac disorders 2.8
Cardiovascular disorder Cardiac disorders 2.9
Zoledronic acid M05BA08 March 2001 Osteonecrosis Musculoskeletal and connective
tissue disorders
4.3
Dibotermin alfa M05BC01 October 2002 Oedema Metabolism and nutrition
disorders
1.9
Effusion General disorders and
administration site conditions
4.5
Strontium ranelate M05BX03 September 2004 Drug rash with eosinophilia and
systemic symptoms
Blood and lymphatic system
disorders
3.2
Aripiprazole N05AX12 June 2004 Cerebrovascular disorder Nervous system disorders 0.7
Verteporfin S01LA01 July 2000 Macular degeneration Eye disorders 6.8
Deferasirox V03AC03 August 2006 Hepatic failure Hepatobiliary disorders 1.9
Sulphur hexafluoride V08DA05 March 2001 Cardiovascular disorder Cardiac disorders 3.2




Miglustat A16AX06 November 2002 Ulcerative colitis Gastrointestinal disorders 4.4





Atazanavir J05AE08 March 2004 Drug effect decreased General disorders and
administration site conditions
0.8
Tenofovir J05AF07 February 2002 Drug effect decreased General disorders and
administration site conditions
1.5
Drug effect decreased General disorders and
administration site conditions
3.1
Renal disorder Renal and urinary disorders 4.1
Renal failure Renal and urinary disorders 6.2
Etravirine J05AG04 August 2008 Epidermal necrosis Skin and subcutaneous tissue
disorders
1.2
Alemtuzumab L01XC04 July 2001 Death General disorders and
administration site conditions
6.6
Bortezomib L01XX32 April 2004 Pericarditis Cardiac disorders 4.0
DHPCs exluded
Agalsidase alfa A16AB03 August 2001 Drug dispensing error Injury, poisoning and procedural
complications
7.5
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Appendix 1
Continued
Drug name ATC Approved Warning System organ class
Time to
DHPC (years)
Protein C algasidase beta A16AB04 August 2001 Product contamination General disorders and
administration site conditions
7.9
Product contamination General disorders and
administration site conditions
8.2
Alglucosidase alfa A16AB07 March 2006 Product quality issue General disorders and
administration site conditions
2.8
Tenecteplase B01AD11 February 2001 Device leakage Injury, poisoning and procedural
complications
0.7
Bivalirudin B01AE06 September 2004 Incorrect dose administered Injury, poisoning and procedural
complications
3.1
Moroctocog alfa B02BD02 April 1999 Circumstance or information
capable of leading to
medication error
Injury, poisoning and procedural
complications
4.1
Thyrotropin alfa H01AB01 March 2000 Product contamination General disorders and
administration site conditions
9.8
Lopinavir/ritonavir J05AE06 March 2001 Circumstance or information
capable of leading to
medication error
Injury, poisoning and procedural
complications
5.5
Incorrect dose administered Injury, poisoning and procedural
complications
6.4
Levetiracetam N03AX14 September 2000 Incorrect dose administered Injury, poisoning and procedural
complications
7.1
*Drug product was eventually withdrawn from the market due to safety reasons. ATC, Anatomical Therapeutic Chemical classification of the WHO; DHPC, Direct Healthcare
Professional Communication.
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